- Home
- THQ vs KURA Comparison
THQ vs KURA Comparison
Compare THQ & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- KURA
- Stock Information
- Founded
- THQ 2014
- KURA 2014
- Country
- THQ United States
- KURA United States
- Employees
- THQ N/A
- KURA N/A
- Industry
- THQ Finance Companies
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THQ Finance
- KURA Health Care
- Exchange
- THQ Nasdaq
- KURA Nasdaq
- Market Cap
- THQ 763.4M
- KURA 700.5M
- IPO Year
- THQ N/A
- KURA N/A
- Fundamental
- Price
- THQ $17.20
- KURA $8.22
- Analyst Decision
- THQ
- KURA Buy
- Analyst Count
- THQ 0
- KURA 14
- Target Price
- THQ N/A
- KURA $24.45
- AVG Volume (30 Days)
- THQ 158.9K
- KURA 2.0M
- Earning Date
- THQ 01-01-0001
- KURA 11-06-2025
- Dividend Yield
- THQ 7.53%
- KURA N/A
- EPS Growth
- THQ N/A
- KURA N/A
- EPS
- THQ N/A
- KURA N/A
- Revenue
- THQ N/A
- KURA $83,279,000.00
- Revenue This Year
- THQ N/A
- KURA $60.25
- Revenue Next Year
- THQ N/A
- KURA $155.10
- P/E Ratio
- THQ N/A
- KURA N/A
- Revenue Growth
- THQ N/A
- KURA N/A
- 52 Week Low
- THQ $15.29
- KURA $5.41
- 52 Week High
- THQ $20.38
- KURA $21.40
- Technical
- Relative Strength Index (RSI)
- THQ 59.60
- KURA 66.50
- Support Level
- THQ $16.76
- KURA $7.86
- Resistance Level
- THQ $17.21
- KURA $8.52
- Average True Range (ATR)
- THQ 0.19
- KURA 0.45
- MACD
- THQ 0.09
- KURA 0.07
- Stochastic Oscillator
- THQ 95.41
- KURA 80.89
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.